Clinical Perspective on Citizen Petition

10/18/01


Click here to start


Table of Contents

Clinical Perspective on Citizen Petition

Clinical Perspective

Clinical Perspective

Clinical Perspective

Clinical Perspective

Clinical Perspective

Safety Presentation

Safety Presentation - Caveats

Safety Presentation - Caveats

NDA Data Introduction

NDA Safety Data

NDA Safety Data Introduction

NDA Safety Data Introduction

Claritin NDA Database

Claritin NDA Database

Claritin NDA Database

Claritin Cardiac Safety

Claritin Metabolic Considerations

Zyrtec NDA Database

Zyrtec NDA Database

Zyrtec NDA Database

Zyrtec Cardiac Safety

Zyrtec Metabolic Considerations

Allegra NDA Database

Allegra NDA Database

Allegra NDA Database

Allegra Cardiac Safety

Allegra Metabolic Considerations

NDA summary

POST-MARKETING

POST-MARKETING

POST-MARKETING - OTC antihistamines

POST-MARKETING Claritin

POST-MARKETING Claritin

POST-MARKETING Claritin

POST-MARKETING Zyrtec

POST-MARKETING Zyrtec

POST-MARKETING Zyrtec

POST-MARKETING Zyrtec

POST-MARKETING Allegra

POST-MARKETING Allegra

POST-MARKETING Allegra

POST-MARKETING

Epidemiology Assessment

Epidemiology Assessment

Epidemiology Assessment

Epidemiology Conclusions:

Overall Clinical/Regulatory Conclusions

Overall Conclusions

Overall Conclusions

Advice Sought from NDAC/PADAC

Author: Robert Meyer